Ubs Group Ag Bio Xcel Therapeutics, Inc. Transaction History

Ubs Group Ag

$527 Billion
Q4 2024

A detailed history of Ubs Group Ag transactions in Bio Xcel Therapeutics, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 1,276,893 shares of BTAI stock, worth $2.95 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,276,893

Previous 13,228 9552.96%

Holding current value

$2.95 Million

Previous $8,000 5800.0%

% of portfolio

0.0%

Previous 0.0%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$0.32 - $0.73 $404,372 - $922,475	1,263,665 Added 9552.96%	1,276,893 $472,000
Q3 2024 Nov 14, 2024	SELL	$0.53 - $1.34 $20,805 - $52,601	-39,255 Reduced 74.8%	13,228 $8,000
Q2 2024 Aug 13, 2024	SELL	$1.14 - $2.97 $107,928 - $281,181	-94,674 Reduced 64.34%	52,483 $67,000
Q1 2024 May 13, 2024	BUY	$1.95 - $4.04 $192,732 - $399,301	98,837 Added 204.55%	147,157 $414,000
Q4 2023 Feb 09, 2024	SELL	$2.32 - $5.51 $70,258 - $166,864	-30,284 Reduced 38.53%	48,320 $142,000
Q3 2023 Nov 09, 2023	SELL	$2.49 - $11.85 $80,506 - $383,134	-32,332 Reduced 29.14%	78,604 $198,000
Q2 2023 Aug 11, 2023	SELL	$6.39 - $28.58 $315,365 - $1.41 Million	-49,353 Reduced 30.79%	110,936 $738,000
Q1 2023 May 12, 2023	BUY	$17.7 - $33.24 $373,027 - $700,533	21,075 Added 15.14%	160,289 $2.99 Million
Q4 2022 Feb 08, 2023	SELL	$10.25 - $22.43 $42,783 - $93,622	-4,174 Reduced 2.91%	139,214 $2.99 Million
Q3 2022 Nov 10, 2022	BUY	$11.19 - $17.89 $295,057 - $471,723	26,368 Added 22.53%	143,388 $1.7 Million
Q2 2022 Aug 10, 2022	SELL	$9.03 - $21.55 $573,802 - $1.37 Million	-63,544 Reduced 35.19%	117,020 $1.54 Million
Q1 2022 May 16, 2022	SELL	$15.0 - $22.83 $290,535 - $442,194	-19,369 Reduced 9.69%	180,564 $3.78 Million
Q4 2021 Feb 14, 2022	SELL	$20.12 - $35.09 $317,735 - $554,141	-15,792 Reduced 7.32%	199,933 $4.06 Million
Q3 2021 Nov 15, 2021	BUY	$23.84 - $32.03 $1.31 Million - $1.77 Million	55,122 Added 34.32%	215,725 $6.55 Million
Q2 2021 Aug 13, 2021	SELL	$29.06 - $38.83 $1.07 Million - $1.43 Million	-36,766 Reduced 18.63%	160,603 $4.67 Million
Q1 2021 May 12, 2021	BUY	$39.04 - $64.6 $4.12 Million - $6.81 Million	105,420 Added 114.65%	197,369 $8.52 Million
Q4 2020 Feb 11, 2021	BUY	$42.46 - $56.58 $171,793 - $228,922	4,046 Added 4.6%	91,949 $4.25 Million
Q3 2020 Nov 12, 2020	BUY	$37.44 - $64.63 $263,165 - $454,284	7,029 Added 8.69%	87,903 $3.81 Million
Q2 2020 Jul 31, 2020	SELL	$17.62 - $58.71 $99,746 - $332,357	-5,661 Reduced 6.54%	80,874 $4.29 Million
Q1 2020 May 01, 2020	SELL	$12.26 - $41.14 $80,290 - $269,425	-6,549 Reduced 7.04%	86,535 $1.93 Million
Q4 2019 Feb 14, 2020	BUY	$4.05 - $14.61 $53,387 - $192,589	13,182 Added 16.5%	93,084 $1.36 Million
Q3 2019 Nov 14, 2019	BUY	$7.04 - $11.77 $30,553 - $51,081	4,340 Added 5.74%	79,902 $563,000
Q2 2019 Aug 14, 2019	BUY	$8.99 - $11.79 $4,270 - $5,600	475 Added 0.63%	75,562 $828,000
Q1 2019 May 14, 2019	BUY	$3.49 - $10.47 $217,657 - $652,972	62,366 Added 490.26%	75,087 $743,000
Q4 2018 Feb 14, 2019	BUY	$2.41 - $7.61 $21,244 - $67,082	8,815 Added 225.68%	12,721 $49,000
Q3 2018 Nov 14, 2018	BUY	$7.51 - $12.99 $5,332 - $9,222	710 Added 22.22%	3,906 $30,000
Q2 2018 Aug 14, 2018	BUY	$7.02 - $11.26 $3,748 - $6,012	534 Added 20.06%	3,196 $29,000
Q1 2018 May 15, 2018	BUY	$9.83 - $11.03 $26,167 - $29,361	2,662 New	2,662 $27,000

Others Institutions Holding BTAI

# of Institutions

Shares Held

8.63M

Call Options Held

34.5K

Put Options Held

59.4K

View Full List

About BioXcel Therapeutics, Inc.

Ticker BTAI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,022,500
Market Cap $64.7M
Description
BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and prop...

More about BTAI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account